Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2010 Apr 15:10:13.
doi: 10.1186/1472-6882-10-13.

Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN)

Harald Matthes  1 , Thomas Krummenerl, Manfred Giensch, Corinna Wolff, Jürgen Schulze
Affiliations
Randomized Controlled Trial

Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN)

Harald Matthes et al. BMC Complement Altern Med. .

Abstract

Background: Probiotics are effective in inflammatory bowel diseases. Clinical effectiveness and dose dependency of E. coli Nissle (EcN) enemas were investigated in ulcerative colitis (UC).

Methods: In a double-blind study, 90 patients with moderate distal activity in UC were randomly assigned to treatment with either 40, 20, or 10 ml enemas (N = 24, 23, 23) containing 10E8 EcN/ml or placebo (N = 20). The study medication was taken once daily for at least 2 weeks. After 2, 4 and/or 8 weeks the clinical DAI was assessed together with tolerance to treatment. Patients who reached clinical DAI <or= 2 within that time were regarded as responders.

Results: According to ITT analysis the number of responders was not significantly higher in the EcN group than in the placebo group (p = 0.4430, 2-sided). However, the Jonckheere-Terpstra rank correlation for dose-dependent efficacy indicated a significant correlation of per-protocol responder rates (p = 0.0446, 2-sided). Time to remission was shortest with EcN 40 ml, followed by EcN 20 ml. The number of adverse events did not differ notably.

Conclusion: In contrast to ITT analysis, efficacy of rectal EcN application was significant in PP and points to EcN as a well tolerated treatment alternative in moderate distal UC.

Trial registration: German Clinical Trials Register DRK00000234.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Patient flow chart.
Figure 2
Figure 2
Time to remission, per-protocol analysis (N = 57) and intention-to-treat analysis (N = 88).
Figure 3
Figure 3
Changes in histological findings in rectum, intention-to-treat analysis (N = 88).
Figure 4
Figure 4
Course of clinical DAI between admission and end of treatment (LOCF), per- protocol analysis (N = 57).
See this image and copyright information in PMC

References

    1. Collins P, Rhodes J. Ulcerative colitis: diagnosis and management. BMJ. 2006;333:340–3. doi: 10.1136/bmj.333.7563.340. - DOI - PMC - PubMed
    1. Zigra PI, Maipa VE, Alamanos YP. Probiotics and remission of ulcerative colitis: a systematic review. Neth J Med. 2007;65:411–8. - PubMed
    1. Lukas M, Bortlik M, Maratka Z. What is the origin of ulcerative colitis? Still more questions than answers. Postgrad Med J. 2006;82:620–5. doi: 10.1136/pmj.2006.047035. - DOI - PMC - PubMed
    1. D'Haens G, Sandborn WJ, Feagan BG. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132:763–86. doi: 10.1053/j.gastro.2006.12.038. - DOI - PubMed
    1. Furuta R, Kusugami K, Goto H. [Enema therapy for ulcerative colitis patients] Nippon Rinsho. 2005;63:845–9. - PubMed

Publication types

MeSH terms

Substances